Christian Posch, Brian D

Slides:



Advertisements
Similar presentations
Jane L. Armstrong, David S. Hill, Christopher S
Advertisements

A Signal Transduction Pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its Correlation with Progression in Human Melanoma  Xuan Qu, Liangliang Shen,
Vemurafenib Induces Senescence Features in Melanoma Cells
Mechanisms of p53 Restriction in Merkel Cell Carcinoma Cells Are Independent of the Merkel Cell Polyoma Virus T Antigens  Roland Houben, Christina Dreher,
Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin  Todd D. Prickett, Brad Zerlanko,
Yongping Shao, Kaitlyn Le, Hanyin Cheng, Andrew E. Aplin 
MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations 
MAGE-C2 Promotes Growth and Tumorigenicity of Melanoma Cells, Phosphorylation of KAP1, and DNA Damage Repair  Neehar Bhatia, Tony Z. Xiao, Kimberly A.
Translational Repression Protects Human Keratinocytes from UVB-Induced Apoptosis through a Discordant eIF2 Kinase Stress Response  Ann E. Collier, Ronald.
Dual Role of Apoptosis-Associated Speck-Like Protein Containing a CARD (ASC) in Tumorigenesis of Human Melanoma  Weimin Liu, Yuchun Luo, Jeffrey H. Dunn,
Kynurenine Increases Matrix Metalloproteinase-1 and -3 Expression in Cultured Dermal Fibroblasts and Improves Scarring In Vivo  Yunyuan Li, Ruhangiz T.
Volume 33, Issue 2, Pages (January 2009)
Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells  Christian Posch,
P90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis  Nicholas Theodosakis, Goran Micevic, Casey G.
Volume 191, Issue 1, Pages (January 2014)
RAF Inhibition Overcomes Resistance to TRAIL-Induced Apoptosis in Melanoma Cells  Anja Berger, Sandra-Annika Quast, Michael Plötz, Nicholas-Frederik Kuhn,
Playing Polo-Like Kinase in NRAS-Mutant Melanoma
BAP1 Has a Survival Role in Cutaneous Melanoma
Playing Polo-Like Kinase in NRAS-Mutant Melanoma
MAPKAP Kinase 2 (MK2)-Dependent and -Independent Models of Blister Formation in Pemphigus Vulgaris  Xuming Mao, Hong Li, Yasuyo Sano, Matthias Gaestel,
Mechanisms of p53 Restriction in Merkel Cell Carcinoma Cells Are Independent of the Merkel Cell Polyoma Virus T Antigens  Roland Houben, Christina Dreher,
Amanda Croft, Kwang H. Tay, Suzanah C. Boyd, Su T. Guo, Chen C
On the TRAIL to Overcome BRAF-Inhibitor Resistance
Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells  Nabanita Mukherjee, Steven.
Valentina Manfé, Edyta Biskup, Peter Johansen, Maria R
Volume 18, Issue 1, Pages (July 2010)
XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation  Manali Phadke, Geoffrey T. Gibney, Carolyn J. Rich,
Ha Linh Vu, Sheera Rosenbaum, Claudia Capparelli, Timothy J
MiR-137 Inhibits the Invasion of Melanoma Cells through Downregulation of Multiple Oncogenic Target Genes  Chonglin Luo, Paul W. Tetteh, Patrick R. Merz,
Rolando Perez-Lorenzo, Kamraan Z. Gill, Che-Hung Shen, Feng X
Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M
IGF-II-Mediated COX-2 Gene Expression in Human Keratinocytes Through Extracellular Signal-Regulated Kinase Pathway  Hye Jung Kim, Tae-Yoon Kim  Journal.
Keiran S.M. Smalley  Journal of Investigative Dermatology 
IQGAP1 and IQGAP3 Serve Individually Essential Roles in Normal Epidermal Homeostasis and Tumor Progression  Christine L. Monteleon, Andrew McNeal, Elizabeth.
Inhibition of PI3K-AKT-mTOR Signaling Sensitizes Melanoma Cells to Cisplatin and Temozolomide  Tobias Sinnberg, Konstantinos Lasithiotakis, Heike Niessner,
Searching for the Chokehold of NRAS Mutant Melanoma
Alexander J. Lakhter, Ravi P. Sahu, Yang Sun, William K
BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma  Wenjing Fu, Shengguo Yi, Lei.
Selective Induction of Apoptosis in Melanoma Cells by Tyrosinase Promoter-Controlled CD95 Ligand Overexpression  Lothar F. Fecker, Christoph C. Geilen,
Regulation of Fibulin-2 Gene Expression by Integrin α3β1 Contributes to the Invasive Phenotype of Transformed Keratinocytes  Dara S. Missan, Sridar V.
The TRAF-Interacting Protein (TRIP) Is a Regulator of Keratinocyte Proliferation  Stéphanie Almeida, Stephan Ryser, Magdalena Obarzanek-Fojt, Daniel Hohl,
Plexin B1 Suppresses c-Met in Melanoma: A Role for Plexin B1 as a Tumor-Suppressor Protein through Regulation of c-Met  Laurel Stevens, Lindy McClelland,
Yao Zhan, Michael S. Dahabieh, Arjuna Rajakumar, Monica C
Inhibition of CRM1-Mediated Nucleocytoplasmic Transport: Triggering Human Melanoma Cell Apoptosis by Perturbing Multiple Cellular Pathways  Gaurav Pathria,
Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells  Nabanita Mukherjee, Steven.
Circulating Tumor Cells and Melanoma Progression
Sema4D, the Ligand for Plexin B1, Suppresses c-Met Activation and Migration and Promotes Melanocyte Survival and Growth  Joanne Soong, Yulin Chen, Elina.
A Bifunctional Approach of Immunostimulation and uPAR Inhibition Shows Potent Antitumor Activity in Melanoma  Fanny Matheis, Markus V. Heppt, Saskia A.
Small Interfering RNA Journal of Investigative Dermatology
SiRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide  Jonathan E. Zuckerman,
Yabin Cheng, Guangdi Chen, Magdalena Martinka, Vincent Ho, Gang Li 
Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma  Soonyean Hwang, Hye-Eun Kim, Michelle Min, Rekha.
Select Cancer Testes Antigens of the MAGE-A, -B, and -C Families Are Expressed in Mast Cell Lines and Promote Cell Viability In Vitro and In Vivo  Bing.
Oncogenic B-RAFV600E Signaling Induces the T-Box3 Transcriptional Repressor to Repress E-Cadherin and Enhance Melanoma Cell Invasion  Suzanah C. Boyd,
Chi-Hyun Park, Youngji Moon, Chung Min Shin, Jin Ho Chung 
Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas  Fang Liu, Juxiang Cao, Jinxiang Wu, Kayleigh Sullivan, James Shen,
Resistance of Human Melanoma Cells Against the Death Ligand TRAIL Is Reversed by Ultraviolet-B Radiation via Downregulation of FLIP  Elke Zeise, Michael.
Insulin-Like Growth Factor-Binding Protein 7 Regulates Keratinocyte Proliferation, Differentiation and Apoptosis  Janna Nousbeck, Ofer Sarig, Nili Avidan,
Mark A. Rovedo, Nancy L. Krett, Steven T. Rosen 
Targeted Depletion of Polo-Like Kinase (Plk) 1 Through Lentiviral shRNA or a Small- Molecule Inhibitor Causes Mitotic Catastrophe and Induction of Apoptosis.
Volume 8, Issue 4, Pages (October 2005)
Macrophage Inhibitory Cytokine-1 Is Overexpressed in Malignant Melanoma and Is Associated with Tumorigenicity  Glen M. Boyle, Julie Pedley, Adam C. Martyn,
BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma  Wenjing Fu, Shengguo Yi, Lei.
Merkel Cell Polyomavirus–Positive Merkel Cell Carcinoma Cells Do Not Require Expression of the Viral Small T Antigen  Sabrina Angermeyer, Sonja Hesbacher,
Nan-Lin Wu, Te-An Lee, Te-Lung Tsai, Wan-Wan Lin 
Deon G. Uffort, Elizabeth A. Grimm, Julie A. Ellerhorst 
Bcl-2 and bcl-xL Antisense Oligonucleotides Induce Apoptosis in Melanoma Cells of Different Clinical Stages  Robert A. Olie, Christoph Hafner, Renzo Küttel,
Jane L. Armstrong, David S. Hill, Christopher S
Roland Houben, Sonja Ortmann, Astrid Drasche, Jakob Troppmair, Marco J
Role and Regulation of STAT3 Phosphorylation at Ser727 in Melanocytes and Melanoma Cells  Masanobu Sakaguchi, Masahiro Oka, Tetsushi Iwasaki, Yasuo Fukami,
Presentation transcript:

Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma  Christian Posch, Brian D. Cholewa, Igor Vujic, Martina Sanlorenzo, Jeffrey Ma, Sarasa T. Kim, Sonja Kleffel, Tobias Schatton, Klemens Rappersberger, Rosie Gutteridge, Nihal Ahmad, Susana Ortiz-Urda  Journal of Investigative Dermatology  Volume 135, Issue 10, Pages 2475-2483 (October 2015) DOI: 10.1038/jid.2015.198 Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Neuroblastoma rat sarcoma viral oncogene homolog (NRAS) mutant cell lines express high levels of Polo-like kinase 1 (Plk1) mRNA. (a) Relative expression of Plk1 in 23 human melanoma cell lines. NRAS mutant melanoma cell lines show higher Plk1 expression compared with non-NRAS and, in particular, to BRAF(V600) mutant cell lines. (b) Plk1 expression in stably transduced primary human melanocytes (PHMs) expressing the indicated NRAS mutations or an empty vector control (E). NRAS(Q61) mutant cells show a significant increase of Plk1 expression on mRNA and protein level compared with empty vector controls, non-oncogenic NRAS(N24) mutants, and NRAS(G12) mutant cells. Bars represent the mean relative expression of Plk1. β-Actin served as an endogenous control (N=3; *P<0.05; mean±SEM). BRAF, v-Raf murine sarcoma viral oncogene homolog B; ΔΔCT, deltadelta threshold cycle. Journal of Investigative Dermatology 2015 135, 2475-2483DOI: (10.1038/jid.2015.198) Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 Dose-dependent reduction of cell viability with inhibitors of mitogen-activated protein kinase/extracellular signal–regulated kinase kinase (MEK) and Polo-like kinase (Plk1). Dose–response curves of five neuroblastoma rat sarcoma viral oncogene homolog (NRAS) mutant melanoma cell lines (WM3629, WM3670, Sk-Mel-2, MM485, and D04) using inhibitors of MEK, Plk1, or their combination. All cell lines were sensitive to MEK and Plk1 inhibition, as well as the combination of both inhibitors (GI50=concentration at 50% growth inhibition; N=3; mean±SD; one unit of inhibitor represents 1 nm of the MEK inhibitor JTP-74057 and 8 nm for the Plk1 inhibitor BI6727). Journal of Investigative Dermatology 2015 135, 2475-2483DOI: (10.1038/jid.2015.198) Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 3 Regulation of cell cycle genes, and p53/p21 signaling members with inhibitors of mitogen-activated protein kinase/extracellular signal–regulated kinase (ERK) kinase (MEK) and Polo-like kinase 1 (Plk1). (a) Hierarchical clustering of mRNA levels in two neuroblastoma rat sarcoma viral oncogene homolog (NRAS) mutant lines in response to the respective inhibitors after 6 and 24 hours of incubation. The expression patterns were similar in both cell lines. Several cell cycle–related genes were affected by the single inhibitors and the MEK/Plk1 combination. (b) Immunoblot analyses of the human melanoma lines Sk-Mel-2 and D04 and corresponding bar graphs for relative protein expression. Reduced phosphoprotein levels of ERK and S6 in MEK inhibitor–treated conditions. Induction of p-AKT in Sk-Mel-2 cells after MEK inhibition. Reduction of p-AKT, p-ERKT, and p-S6, as well as induction of CCNB1, by the combination treatment (*>200%; mean±SD; N=3). Journal of Investigative Dermatology 2015 135, 2475-2483DOI: (10.1038/jid.2015.198) Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 4 Induction of apoptosis and cell cycle arrest with the mitogen-activated protein kinase/extracellular signal–regulated kinase kinase/Polo-like kinase 1 (MEK/Plk1) combination. (a) Earlier and pronounced decrease of cell viability over time and (b) earlier and stronger induction of caspase-3/7 activity with the MEK/Plk1 combination. (c) G0/G1 arrest in MEK inhibitor (MEKi)–treated groups and G2/M arrest in BI6727-treated cells. The combination of both inhibitors caused a dose-dependent dual G1 (red) and G2/M (blue) arrest. (d) Double thymidine block and time-course analyses of cell cycle progression showed a G1 arrest with the MEKi. Progressing cells in the combinational treatment group succumb to G2/M arrest induced by the Plk1 inhibitor (Plk1i). (e) The thymidine-nocodazole block revealed continuous G2/M arrest after Plk1i treatment. (N=3; mean±SD; MEKi(JTP-74017)=20 nm; Plk1i(BI6727)=100 nm). Journal of Investigative Dermatology 2015 135, 2475-2483DOI: (10.1038/jid.2015.198) Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 5 (a) P53 signaling affects Polo-like kinase 1 (Plk1) and mitogen-activated protein kinase/extracellular signal–regulated kinase kinase (MEK)/Plk1 inhibitor efficacy. Stable knockdown of p53 reduced the activity of Plk1 and MEK/Plk1 inhibition. P53 interference had no effect on viability in cells treated with the MEK inhibitor (MEKi) only, or on vehicle-treated cells. (b) Additional Inhibition of Chk1/2 markedly reduced viability in MEK/Plk1–treated compared with single inhibitor or vehicle-treated controls in a biphasic manner. (c) Immunoblot analyses of p-p53 and Plk1 in all 10 neuroblastoma rat sarcoma viral oncogene homolog (NRAS) mutant cell lines used in this study. All cells, except MM485, express p-p53. Plk1 protein expression was pronounced in NRAS(Q61) mutant cells. (d) Relative expression of the respective proteins compared with β-actin (N=3; mean±SD; SCR=scramble control shRNA; MEKi(JTP-74057)=20 nm; Plk1 inhibitor (Plk1i)(BI6727)=100 nm; Chk1/2i=PF-0477736). A.u., arbitrary unit; shRNA, short hairpin RNA. Journal of Investigative Dermatology 2015 135, 2475-2483DOI: (10.1038/jid.2015.198) Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 6 Tumor size reduction of neuroblastoma rat sarcoma viral oncogene homolog (NRAS) mutant xenografts with the mitogen-activated protein kinase/extracellular signal–regulated kinase kinase/Polo-like kinase 1 (MEK/Plk1) combination. (a) Treatment of established mouse xenografts showed tumor size reduction after initiation of treatment (day 0) with the combination of an MEK inhibitor (MEKi) (2 mg kg−1 per day) and Plk1 inhibitor (Plk1i) (50 mg kg−1 per week), but not with either MEKi or Plk1i alone (cell lines: Sk-Mel-2, WM3670; MEKi: JTP-74057; Plk1i: BI6727; n=4). Results are displayed as the mean change in tumor volume at indicated time points±SD. (b) Corresponding immunoblot analyses of mouse tumors after 3 weeks of treatment with the indicated conditions. Journal of Investigative Dermatology 2015 135, 2475-2483DOI: (10.1038/jid.2015.198) Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions